Trials / Terminated
TerminatedNCT06516510
A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer
A Randomised, Multi-centre, Intra-patient Imaging and Dosimetry Crossover Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer
- Status
- Terminated
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Blue Earth Therapeutics Ltd · Industry
- Sex
- Male
- Age
- 60 Years
- Healthy volunteers
- Not accepted
Summary
A randomised, multi-centre, intra-patient imaging and dosimetry crossover study of lutetium (177Lu) rhPSMA 10.1 and lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in patients with non-curative metastatic prostate cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lutetium (177Lu) rhPSMA 10.1 and Pluvicto® | Radiopharmaceutical |
Timeline
- Start date
- 2024-10-31
- Primary completion
- 2025-08-15
- Completion
- 2025-08-15
- First posted
- 2024-07-24
- Last updated
- 2025-09-25
Locations
6 sites across 3 countries: United States, Netherlands, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06516510. Inclusion in this directory is not an endorsement.